Loading data for LPCN — first visit, this takes a few seconds.
Lipocine Inc. (LPCN)
NasdaqCM: LPCN
· 即時價格 · USD
2.30
+0.01 (0.44%)
收盤價： Sep 11, 2026, 8:00 PM
2.27
+0.89%
盤後: 4:10 PM
股價、關鍵數字和最新消息，都在這一頁。
Lipocine Inc.（LPCN）股價、分析與資料
無可用資料
| 買價 | 1.68 |
| 市值 | 18.7M |
| 營收 (ttm) | 1.57M |
| 淨利（ttm） | -11.9M |
| 0.47 | |
| -1.85 | |
| n/a | |
| -1.83 | |
| P/B (ttm) | 0.86 |
| P/S (ttm) | 11.92 |
| 財報日期 | Aug 14, 2025 |
| 賣價 | 2.95 |
| 成交量 | 19,839 |
| 20 日平均成交量 | 58,190 |
| 開盤價 | 2.22 |
| 前收盤價 | 2.29 |
| 當日區間 | 2.22 - 2.34 |
| 52 週範圍 | 1.81 - 12.37 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone lau...
完整的公司簡介財報驚奇
Lipocine 已於 Aug 4, 2026 公布季度財報：
- 營收為 $190.1K 低於預期 $0, 年增 -69.48% 下滑.
- 每股盈餘為 -0.32 超出預期 0.08, 年增 21.95% 成長.
第 1 頁，共 2 頁